FDA warns Florida clinical investigator over consent failings in INSTI HIV self-test study
CBER's warning letter cites informed consent, unapproved consent-form changes and weak oversight at a site running bioLytical's CLS-003 study; the investigator did not respond to the Form 483.
The US Food and Drug Administration's Center for Biologics Evaluation and Research has issued a warning letter, dated 27 August 2026, to Stephen J. Fallon, Ph.D., of Wilton Manors, Florida. It follows a Bioresearch Monitoring inspection of his clinical study site between 2 and 13 June 2025. The study was Protocol CLS-003, evaluating the performance, usability and result interpretation of the INSTI HIV Self-Test among observed intended users in the US.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.